Cortical thinning and metabolic reduction can be possible imaging biomarkers for Alzheimer's disease (AD) diagnosis and monitoring. Many techniques have been developed for the cortical measurement and widely used for the clinical statistical studies. However, the measurement consistency of individuals, an essential requirement for a clinically useful technique, requires proper further investigation. Here we leverage our previously developed BSIM technique 1 to measure cortical thickness and thinning and use it with longitudinal MRI from ADNI to investigate measurement consistency and spatial resolution. 10 normal, 10 MCI, and 10 AD subjects in their 70s were selected for the study. Consistent cortical thinning patterns were observed in all baseline and follow up images. Rapid cortical thinning was shown in some MCI and AD cases. To evaluate the correctness of the cortical measurement, we compared longitudinal cortical thinning with clinical diagnosis and longitudinal PET metabolic reduction measured using 3D-SSP technique 2 for the same person. Longitudinal MR cortical thinning and corresponding PET metabolic reduction showed high level pattern similarity revealing certain correlations worthy of further studies. Severe cortical thinning that might link to disease conversion from MCI to AD was observed in two cases. In summary, our results suggest that consistent cortical measurements using our technique may provide means for clinical diagnosis and monitoring at individual patient's level and MR cortical thinning measurement can complement PET metabolic reduction measurement.